Clinical trial
An Exploratory Phase 1/2 Trial To Evaluate The Safety And Efficacy Of JCAR017 Combinations In Subjects With Relapsed/Refractory B-Cell Malignancies (PLATFORM)
NCT03310619 is registered in ClinicalTrials.gov with Celgene as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Exploratory Phase 1/2 Trial To Evaluate The Safety And Efficacy Of JCAR017 Combinations In Subjects With Relapsed/Refractory B-Cell Malignancies (PLATFORM)
- Lead sponsor
- Celgene
- Phase
- Phase 1/2
- Overall status
- Completed
- Start date
- December 20, 2017
- Completion date
- February 15, 2023
- Enrollment
- 62 (actual)
- Sites
- 9
Conditions
As the registry lists them; a condition with its own page is linked.